Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. Registration information to attend the virtual sessions can be found here. “We will have a strong presenc